mRNA Personalized Cancer Vaccines and Immune-Oncology
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: 28 February 2027 | Viewed by 962
Special Issue Editor
Special Issue Information
Dear Colleagues,
The Special Issue "mRNA Personalized Cancer Vaccines and Immune-Oncology" explores the design, manufacturing, and clinical translation of tailor-made mRNA or self-amplifying RNA vaccines that encode patient-specific neoantigens, tumor-associated antigens, or shared driver mutations. It integrates lipid-nanoparticle and polymeric delivery systems, in situ co-stimulatory signals, and combination regimens with checkpoint inhibitors, CAR-T cells, oncolytic viruses, or metabolic modulators. Studies on vaccine-elicited T-cell/B-cell repertoire dynamics, innate sensing, tumor microenvironment remodeling, biomarker-guided patient selection, rapid GMP production, and regulatory frameworks are welcomed, spanning early-phase trials to late-stage efficacy across solid and hematologic malignancies.
Dr. Praveen Neeli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neoantigen prediction
- mRNA vaccine
- cancer immunotherapy
- immuno-oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
